Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free ATXI Stock Alerts

Avenue Therapeutics (ATXI) Competitors

Avenue Therapeutics logo
$0.26 -0.02 (-8.23%)
As of 08/14/2026 02:04 PM Eastern
Compare

ATXI vs. XRTX, SPRC, GLMD, UPC, and SXTP

Should you buy Avenue Therapeutics stock or one of its competitors? Avenue Therapeutics's main competitors and comparable companies include XORTX Therapeutics (XRTX), SciSparc (SPRC), Galmed Pharmaceuticals (GLMD), Universe Pharmaceuticals (UPC), and 60 Degrees Pharmaceuticals (SXTP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Avenue Therapeutics compare to XORTX Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A
XORTX TherapeuticsN/AN/A-$2.66M-$2.63N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

XORTX Therapeutics' return on equity of -150.01% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
XORTX Therapeutics N/A -150.01%-106.53%

Avenue Therapeutics has a beta of -0.2, meaning that its stock price is 120% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

In the previous week, XORTX Therapeutics had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for XORTX Therapeutics and 0 mentions for Avenue Therapeutics. XORTX Therapeutics' average media sentiment score of 1.08 beat Avenue Therapeutics' score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Avenue Therapeutics Neutral
XORTX Therapeutics Positive

Summary

XORTX Therapeutics beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to SciSparc?

Avenue Therapeutics (NASDAQ:ATXI) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
SciSparc
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, SciSparc had 7 more articles in the media than Avenue Therapeutics. MarketBeat recorded 7 mentions for SciSparc and 0 mentions for Avenue Therapeutics. SciSparc's average media sentiment score of 0.68 beat Avenue Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company Overall Sentiment
Avenue Therapeutics Neutral
SciSparc Positive

Avenue Therapeutics has a beta of -0.2, suggesting that its share price is 120% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.78, suggesting that its share price is 178% more volatile than the broader market.

Avenue Therapeutics has higher earnings, but lower revenue than SciSparc.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A
SciSparc$860K4.37-$12.18MN/AN/A

SciSparc's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
SciSparc N/A N/A N/A

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

SciSparc beats Avenue Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galmed PharmaceuticalsN/AN/A-$10.31M-$0.91N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for Avenue Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.30 beat Avenue Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Galmed Pharmaceuticals Neutral
Avenue Therapeutics Neutral

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Galmed Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Galmed Pharmaceuticals' return on equity of -35.32% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Galmed PharmaceuticalsN/A -35.32% -30.94%
Avenue Therapeutics N/A -471.57%-296.50%

Summary

Galmed Pharmaceuticals beats Avenue Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Universe Pharmaceuticals' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Avenue Therapeutics N/A -471.57%-296.50%

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Universe Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market.

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 0 mentions for Avenue Therapeutics. Universe Pharmaceuticals' average media sentiment score of 1.43 beat Avenue Therapeutics' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Universe Pharmaceuticals Positive
Avenue Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Universe Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.74M1.60-$3.67MN/AN/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A

Summary

Universe Pharmaceuticals beats Avenue Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

60 Degrees Pharmaceuticals currently has a consensus target price of $13.85, suggesting a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Avenue Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
Avenue Therapeutics N/A -471.57%-296.50%

60 Degrees Pharmaceuticals has a beta of 2.54, indicating that its stock price is 154% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market.

60 Degrees Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M2.25-$7.36M-$8.92N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A

In the previous week, 60 Degrees Pharmaceuticals had 4 more articles in the media than Avenue Therapeutics. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Avenue Therapeutics. Avenue Therapeutics' average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.28 indicating that Avenue Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Neutral
Avenue Therapeutics Neutral

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

60 Degrees Pharmaceuticals beats Avenue Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATXI vs. The Competition

Export
MetricAvenue TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$849K$11.92B$7.02B$13.06B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio0.01779.99271.2725.33
Price / SalesN/A749.47588.5578.45
Price / CashN/A66.4570.4850.90
Price / Book0.1311.6012.926.25
Net Income-$10.38M$2.77B$3.45B$347.82M
7 Day Performance0.98%0.14%1.16%1.08%
1 Month Performance-0.92%0.06%1.37%0.82%
1 Year Performance-54.81%145.15%62.53%20.99%

Avenue Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATXI
Avenue Therapeutics
N/A$0.26
-8.2%		N/A-50.5%$849KN/A0.014
XRTX
XORTX Therapeutics
0.9206 of 5 stars		$2.15
-1.8%		N/A-50.7%$3.91MN/AN/AN/A
SPRC
SciSparc
0.5707 of 5 stars		$6.70
-2.8%		N/A-85.1%$3.82M$860KN/A4
GLMD
Galmed Pharmaceuticals
0.7787 of 5 stars		$0.57
-1.0%		N/A-64.7%$3.79MN/AN/A20
UPC
Universe Pharmaceuticals
1.3603 of 5 stars		$6.08
-1.3%		N/A+58.7%$3.41M$17.74MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel